Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 983-991

  Denkert, Carsten ^a,b   Von Minckwitz, Gunter ^d,e   Brase, Jan C ^g   Sinn, Bruno V ^a   Gade, Stephan ^d   Kronenwett, Ralf ^g,i   Pfitzner, Berit M ^a   Salat, Christoph ^k   Loi, Sherene ^q,r   Schmitt, Wolfgang D ^a   Schem, Christian ^j   Fisch, Karin ^g   Darb Esfahan, Silvia ^a   Mehta, Keyur ^d   Sotiriou, Christos ^r   Wienert, Stephan ^a   Klare, Peter ^b   André, Fabrice ^s   Klauschen, Frederick ^h   Blohmer, Jens Uwe ^c   Krappmann, Kristin ^g   Schmidt, Marcus ^l   Tesch, Hans ^f   Kümmel, Sherko ^m   Sinn, Peter ⁿ   Jackisch, Christian ^o   Dietel, Manfred ^a   Reimer, Toralf ^p   Untch, Michael ^a   Loibl, Sibylle ^d,o   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Praxisklinik and Breast Center   (Germany)

^d HELIOS KLINIKUM BERLIN BUCH   (Germany)

^e German Breast Group   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g Bethanien Krankenhaus Frankfurt   (Germany)

^h Sividon Diagnostics   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j UNIVERSITY OF KIEL   (Germany)

^k Onkologische Schwerpunktpraxis   (Germany)

^l JOHANNES GUTENBERG UNIVERSITY   (Germany)

^m KLINIKEN ESSEN MITTE   (Germany)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o SANA KLINIKUM OFFENBACH   (Germany)

^p Klinikum Su Anddie   (Germany)

^q PETER MACCALLUM CANCER CENTRE   (Australia)

^r JULES BORDET INSTITUTE   (Belgium)

^s INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BEVACIZUMAB; CARBOPLATIN; CD8ALPHA ANTIGEN; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; RANTES; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84927138902     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.1967     Document Type: Article

References (33)

1. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
2. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, openlabel, multicentre, phase 3 trial. Lancet 379:633-640, 2012
3. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014
4. Untch M, Fasching PA, Konecny GE, et al: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-3357, 2011
5. von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15:747-756, 2014
6. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Presented at the San Antonio Breast Cancer Symposium, December 10-14, 2013 (abstr S5-01)
7. Denkert C, Loibl S, Noske A, et al: Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
8. Issa-Nummer Y, Darb-Esfahani S, Loibl S, et al: Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer: A substudy of the neoadjuvant GeparQuinto trial. PLoS One 8:e79775, 2013
9. West NR, Milne K, Truong PT, et al: Tumorinfiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13:R126, 2011
10. Yamaguchi R, Tanaka M, Yano A, et al: Tumorinfiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 43:1688-1694, 2012
11. Schmidt M, Hellwig B, Hammad S, et al: A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin - C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18:2695-2703, 2012
12. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
13. Gu-Trantien C, Loi S, Garaud S, et al: CD4- follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 123:2873-2892, 2013
14. Ignatiadis M, Singhal SK, Desmedt C, et al: Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol 30:1996-2004, 2012
15. Bianchini G, Gianni L: The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 15:e58-e68, 2014
16. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
17. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
18. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
19. Galluzzi L, Senovilla L, Zitvogel L, et al: The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215-233, 2012
20. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184, 2005
21. Wienert S, Heim D, Saeger K, et al: Detection and segmentation of cell nuclei in virtual microscopy images: A minimum-model approach. Sci Rep 2:503, 2012
22. Wienert S, Heim D, Kotani M, et al: Cognition-Master: An object-based image analysis framework. Diagn Pathol 8:34, 2013
23. Denkert C, Loibl S, Kronenwett R, et al: RNAbased determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. Ann Oncol 24:632-639, 2013
24. Bohmann K, Hennig G, Rogel U, et al: RNA extraction from archival formalin-fixed paraffinembedded tissue: A comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 55:1719-1727, 2009
25. Polley MY, Leung SC, McShane LM, et al: An international Ki67 reproducibility study. J Natl Cancer Inst 105:1897-1906, 2013
26. Hato SV, Khong A, de Vries IJ, et al: Molecular pathways: The immunogenic effects of platinumbased chemotherapeutics. Clin Cancer Res 20: 2831-2837, 2014
27. Dieci MV, Criscitiello C, Goubar A, et al: Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 25:611-618, 2014
28. Schalper KA, Velcheti V, Carvajal D, et al: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:2773-2782, 2014
29. West NR, Kost SE, Martin SD, et al: Tumourinfiltrating FOXP3(-) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108:155-162, 2013
30. Salama P, Phillips M, Grieu F, et al: Tumorinfiltrating FOXP3- T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186-192, 2009
31. Jacquemier J, Bertucci F, Finetti P, et al: High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 130:96-104, 2012
32. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25:1544-1550, 2014
33. Salgado R, Denkert C, Demaria S, et al: Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs-working group 2014. Ann Oncol [epub ahead of print on September 11, 2014]